Chiasma Stock News

Company to host conference call and webcast at 5:00 p.m. ETNEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced

\-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

Analysts predict that Chiasma Inc (NASDAQ:CHMA) will report earnings of ($0.40) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Chiasma’s earnings, with t

On Wednesday morning, Chiasma, Inc. (NASDAQ: CHMA) announced the pricing of a public offering of common stock and pre-funded warrants. Naturally, investors are not thrilled about the company's decisi

Chiasma, Inc. (CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platfor

Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) ADC Therapeutics SA (NYSE:...

Chiasma, Inc. (CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platfor

On Friday, June 26, 2020, the FDA approved CHMA's Mycapssa. Shares fell on the news to reflect a market cap of ~$250MM and an enterprise valuation of less than

On Friday, June 26, 2020, the FDA approved CHMA's Mycapssa. Shares fell on the news to reflect a market cap of ~$250MM and an enterprise valuation of less than

Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Chiasma (CHMA – Research Report) today and set a price

Acceleron's sotatercept phase 2 trial yields positive data. Insmed reports positive phase 2 data from the WILLOW study. Chiasma's Mycapssa capsules get FDA appr

Chiasma, Inc. (CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance